Bimagrumab
Anti-ActRIIB monoclonal antibody being tested with semaglutide for muscle preservation during weight loss.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
The most-watched non-incretin candidate in the obesity space. Designed to preserve muscle while semaglutide drives fat loss.
- Class
- Anti-ActRIIB monoclonal antibody
- Sponsor
- Eli Lilly (acquired from Versanis)
- Stage
- Phase 3
- Lead use case
- Muscle preservation alongside GLP-1 therapy
What it is
Bimagrumab is a fully human monoclonal antibody that binds and inhibits activin receptor type II (ActRIIB), the shared receptor through which myostatin and activin signal to suppress muscle growth. Originally developed for sarcopenia and inclusion body myositis, it found its most consequential application as a candidate for preserving muscle during the rapid weight loss produced by GLP-1 therapy.
Current research status
Eli Lilly acquired Versanis Bio (the previous bimagrumab developer) in 2023 specifically to advance the molecule into Phase 3 trials in combination with tirzepatide. The Phase 2 BELIEVE trial showed bimagrumab + semaglutide produced more fat loss and better lean-mass preservation than semaglutide alone. The Phase 3 program is the gating event for adoption.
Mechanistic rationale
Myostatin and activin both signal through ActRIIB to activate Smad2/3 and ultimately suppress muscle protein synthesis. Blocking the receptor produces increased muscle mass in animal models — sometimes dramatically. In the obesity setting, the rationale is that pairing bimagrumab with a GLP-1 agonist could shift the composition of weight loss toward fat rather than the typical 25–40% lean-mass component.
Available evidence
BELIEVE Phase 2 trial (Heymsfield et al., JAMA 2021) — Adults with overweight/obesity and T2D received bimagrumab vs placebo over 48 weeks. Bimagrumab produced ~20.5% reduction in fat mass and ~3.6% increase in lean mass vs essentially flat lean mass on placebo.[1]
Subsequent work has paired bimagrumab with semaglutide; Phase 2 readouts have shown the combination produces better fat-vs-lean-mass partitioning than semaglutide alone.
Why it's interesting
This is the most evidence-backed pharmacologic answer to the GLP-1 muscle-preservation problem. The combination strategy — pair the most effective fat-loss class with a targeted muscle-preserving agent — is a clean solution to one of the most discussed concerns about modern weight-loss medicine. If Phase 3 holds up, the standard of care for obesity could shift to combination therapy.
Limitations & risks
ActRIIB blockade has broader downstream effects than muscle alone — potential effects on bone, cardiovascular tissue, and endocrine signaling are part of the long-term safety question. The cost of adding an antibody therapy on top of GLP-1 therapy is non-trivial and will shape access. Phase 3 confirmation in obesity is the gating event; the bimagrumab earlier development in inclusion body myositis did not produce a clinical efficacy result, which is a useful reminder that promising mechanisms don't always translate into all expected indications.
Community discussion notes
Bimagrumab is the bridge between the muscle-preservation conversation in fitness communities and the obesity-pharmacology conversation in clinical medicine. Both groups are watching this molecule closely; the Phase 3 readouts will substantially shape both discourses.
The takeaway
Among the 15 emerging peptides on this page, bimagrumab has the most direct line to changing standard clinical practice within the next two to three years. The mechanism is grounded, the Phase 2 data is supportive, and the use case maps to a problem millions of GLP-1 users currently face.
References
- Heymsfield SB, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity. JAMA Netw Open. 2021;4(1):e2033457. https://pubmed.ncbi.nlm.nih.gov/33439265/
- Lach-Trifilieff E, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy. Mol Cell Biol. 2014;34(4):606-618. https://pubmed.ncbi.nlm.nih.gov/24298022/